Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Transthyretin Amyloidosis Companies

ID: MRFR/Pharma/4697-HCR
100 Pages
Rahul Gotadki
Last Updated: February 16, 2025
Transthyretin Amyloidosis (ATTR) is a rare, progressive condition caused by the accumulation of abnormal deposits of amyloid protein, particularly in the heart and peripheral nerves. The disorder can manifest in hereditary (familial) forms or occur sporadically (wild-type ATTR).
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Transthyretin Amyloidosis Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.64%
2024 Market Size$ 5.98 Billion
2025 Market Size$ 6.45 Billion
2035 Market Size$ 12.18 Billion
Key Players
Alnylam Pharmaceuticals
Pfizer
Bristol-Myers Squibb
Ionis Pharmaceuticals
Eisai Co.
Ltd.
Opportunities
  • Advancements in Therapeutic Options
  • Emerging Markets and Global Expansion
  • Growing Awareness and Education Initiatives

Top Industry Leaders in the Transthyretin Amyloidosis Market

Transthyretin Amyloidosis Market

Latest Transthyretin Amyloidosis Companies Updates

BioMarin Pharmaceutical releases promising early data from a Phase 2 clinical trial of BMN-351, a novel investigational therapy aiming to address the underlying cause of ATTR by correcting the defective sodium chloride cotransporter.

Horizon Therapeutics receives FDA approval for Krystexxa® (burokalifex) extended-release tablets for treating hypokalemia (low potassium levels), a common symptom in ATTR

List of Transthyretin Amyloidosis Key companies in the market:

  • Prothena Corporation plc.
  • Pfizer Inc.
  • Ionis Pharmaceuticals Inc.
  • Valeant Pharmaceuticals International Inc.
  • Celgene Corporation
  • Takeda Pharmaceutical Company Ltd.
  • Johnson and Johnson Pvt. Ltd.
  • GlaxoSmithKline plc
  • Alnylam Pharmaceuticals Inc.